Mission Statement, Vision, & Core Values (2026) of CanSino Biologics Inc.

Founded in 2009, CanSino Biologics Inc. has grown into a global vaccine innovator-headquartered in Tianjin and notably the first 'A+H' dual-listed vaccine company in China, traded as 6185.HK on the Hong Kong Stock Exchange and 688185 on the Shanghai Stock Exchange-operating production sites in Mexico, Pakistan and Malaysia while advancing a pipeline targeting meningitis, Ebola, pneumonia, tuberculosis and COVID-19; since its 2022 rebranding the company has anchored its strategy in the mission 'To provide the world with innovative, high-quality and accessible vaccines', the vision 'Innovation for a safer world', and a compact set of core values-Respect, Agility, Innovation, Superior in quality and Engagement-that drive its research, manufacturing and global access efforts.

CanSino Biologics Inc. (6185.HK) - Intro

• Founded: 2009 (Tianjin, China)
• Listings: HKEX 6185.HK; SSE 688185 (A+H dual listing)
• Global manufacturing footprint includes facilities/partnerships in Mexico, Pakistan, Malaysia
• Therapeutic focus: meningococcal diseases, Ebola, pneumococcal disease, TB, COVID‑19 and other infectious diseases

• Mission: Develop, manufacture and deliver safe, effective and affordable vaccines to protect global public health and improve population resilience against infectious diseases.
• Vision: Be a globally recognized vaccine innovator that accelerates equitable access to life‑saving immunizations through science, scalable manufacturing and international partnerships.
• Core values:
  • Science‑driven innovation - prioritizing R&D rigor and evidence
  • Patient & public health focus - accessibility and affordability
  • Quality & compliance - GMP, regulatory excellence and safety
  • Collaboration - global partnerships and local manufacturing to expand reach
  • Integrity & transparency - ethical conduct and stakeholder accountability

• Advance pipeline: prioritize late‑stage development for vaccines with high unmet need (COVID‑19 boosters, pneumococcal, TB, Ebola candidates).
• Scale manufacturing: expand capacity in China and abroad to ensure rapid supply during outbreaks and to serve low‑ and middle‑income markets.
• Regulatory & market access: secure WHO prequalification, emergency use listings and local approvals to enable global distribution.
• Sustain R&D investment to maintain competitive adenovirus vector platform and develop next‑generation formulations.

• Portfolio prioritization follows global burden and market access potential - e.g., targeting pneumonia/TB and pandemic‑preparedness vaccines where impact is highest.
• Investment in international production reduces supply risk and supports WHO/regional procurement channels.
• Commitment to regulatory approvals (EUL/WHO PQ) aims to unlock UN/WHO procurement and donor programs for low‑income countries.

• Board oversight aligns R&D priorities with long‑term public health impact and commercial sustainability.
• Public listings (HK & Shanghai) increase transparency, reporting frequency and investor scrutiny - driving disciplined capital allocation.
• Partnerships with governments and NGOs enable rapid deployment during outbreaks while supporting local manufacturing transfer and workforce development.

• Revenue and profitability are affected by episodic demand (pandemic waves, booster campaigns) and contestable tender markets; therefore, pipeline success and WHO listings materially influence medium‑term revenue visibility.
• R&D cadence and regulatory milestones (phase II/III readouts, emergency/standard approvals) are key stock catalysts and strategic validation of the company's mission.

CanSino Biologics Inc. (6185.HK) - Overview

• To provide the world with innovative, high-quality and accessible vaccines.

• To be a global leader in preventive and therapeutic vaccines, delivering scalable biologics that reduce infectious disease burden worldwide.

• Science-led innovation - prioritizing R&D rigor, translational science and platform versatility.
• Patient and public health focus - safety, efficacy and equitable access guide product decisions.
• Quality and compliance - GMP manufacturing, regulatory alignment and continuous quality improvement.
• Collaboration and partnerships - public-private, academic and global health alliances to amplify impact.
• Transparency and responsibility - data-driven reporting, ethical conduct and supply reliability.

• R&D pipeline expansion across infectious diseases and oncology-adjacent platforms.
• Manufacturing scale and tech transfer to secure supply chains for low- and middle-income countries.
• Regulatory diversification: simultaneous submissions to WHO, regional authorities and national regulators.
• Commercial access strategies including tiered pricing, licensing and partner distribution agreements.

• Portfolio prioritization favors candidates with clear public-health impact and scalable manufacturing pathways.
• Partner selection emphasizes geographic reach and capability to support equitable distribution.
• Capital allocation balances near-term commercial scale (vaccine production lines) with longer-term platform R&D.

• Public listing and capital markets access (ticker 6185.HK) support continued factory expansion and R&D funding.
• Revenue streams are diversified between domestic contracts, export sales and collaboration/licensing agreements.
• Manufacturing capacity and throughput are central KPIs tied directly to the 'accessible' element of the mission.

CanSino Biologics Inc. (6185.HK) - Mission Statement

• Mission focus: translate vaccine science into scalable products for epidemic preparedness and routine prevention.
• Strategic pillars: rapid-response platforms, global regulatory alignment, scalable manufacturing, and equitable access.
• Operational emphasis: strengthen partnerships with public-health agencies, NGOs, and commercial partners to expand reach.

• The word 'innovation' signals CanSino's commitment to next-generation vaccine platforms (viral vectors, protein subunits, etc.) and platform adaptability for emerging pathogens.
• 'Safer world' frames the company's broader objective of contributing to global public-health security through both pandemic-response products and routine immunization solutions.
• Since 2022 this vision has been the organizing principle driving R&D prioritization, investments in manufacturing scale-up, and global distribution strategies.

• Science-led: Invest in evidence-based development, adaptive trial designs, and robust clinical endpoints.
• Speed with safety: Emphasize accelerated development timelines while maintaining regulatory compliance and pharmacovigilance.
• Global access: Commit to regulatory filings and partnerships to enable product availability across low-, middle-, and high-income markets.
• Collaboration: Leverage global alliances for co-development, licensing, and manufacturing to expand capacity and reach.

• R&D prioritization: Platform innovation (viral vectors, novel adjuvants) and adaptable vaccine constructs for rapid pivoting to emerging pathogens.
• Manufacturing: Capacity expansion and contract-manufacturing partnerships to meet surge demand while maintaining quality standards.
• Regulatory & access strategy: Pursue WHO listings, national authorizations, and licensing agreements to ensure uptake in diverse markets.
• Stakeholder engagement: Collaborate with governments, multilateral organizations, and NGOs to align distribution with public-health priorities.

CanSino Biologics Inc. (6185.HK) - Vision Statement

Mission pillars driving this vision:

• Develop and deploy safe, effective, and affordable vaccines at scale
• Advance platform technologies (viral vectors, protein subunits, recombinant platforms) to shorten development timelines
• Partner globally to expand equitable access and strengthen health systems

Core Values and How They Shape Strategy

• Respect - fosters diversity across R&D teams, clinical partners, and global distribution networks to accelerate culturally competent deployment of vaccines.
• Agility - underpins rapid pivoting in response to emerging variants and outbreak dynamics, enabling accelerated clinical development and regulatory submissions.
• Innovation - drives continuous investment in next-generation platforms and adjuvant strategies to improve immunogenicity and manufacturing yields.
• Superior in quality - commits to GMP manufacturing standards, robust batch release testing, and international regulatory compliance to maintain product integrity.
• Engagement - ensures active collaboration with governments, WHO, local health authorities, and community stakeholders for effective rollout.

Operationalization: Metrics and Real-World Impact

Key measurable indicators the company emphasizes to translate vision into outcomes:

• Clinical pipeline breadth: multiple candidates across phases (early to late-stage) leveraging adenovirus vector and protein platforms.
• Manufacturing capacity: multi-site GMP capacity scaled for multi-million dose annual output and strategic fill-finish partnerships.
• Regulatory milestones: emergency use authorizations and full approvals across jurisdictions to expand market access.
• R&D intensity: sustained R&D spend as a percentage of revenue to maintain pipeline velocity and platform improvements.

Culture and Governance Aligned with Values

• Board and management KPIs include time-to-clinic metrics, batch quality indices, and partnership reach to ensure alignment of governance with mission-driven goals.
• Talent strategy emphasizes cross-functional teams, international hires, and continuous learning to embed Respect and Agility.
• Quality systems integrate regulatory feedback loops and external audits to sustain Superior in quality.

Investor- and stakeholder-facing communication ties these operational metrics to financial health and strategic priorities; for detailed financial context and recent performance analysis see: Breaking Down CanSino Biologics Inc. Financial Health: Key Insights for Investors